---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-23-000013"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2023-03-29T23:59:59+00:00"
generated_at: "2026-06-17T10:47:42.240990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aerovate reports FY2022 net loss of $51.5M; cash runway into H2 2025

## Summary
- Net loss of $51.5M for FY2022 vs $23.0M in FY2021; R&D expenses $38.6M (up from $15.0M).
- Cash, cash equivalents and investments $129.2M as of Dec 31, 2022; sufficient to fund operations into H2 2025.
- IMPAHCT Phase 2b/3 trial of AV-101 for PAH ongoing; topline data expected Q4 2023 or Q1 2024.
- Four patents issued in 2022; management team strengthened with four new SVPs.
- Board appointed Donald Santel; expanded IP portfolio.

## SEC filing metadata
- accession: 0001798749-23-000013
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2023-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000013/0001798749-23-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000013/tmb-20230329x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-23-000013
- JSON: https://secwatch.observer/filing/0001798749-23-000013.json
- Plain text: https://secwatch.observer/filing/0001798749-23-000013.txt

## Key facts
- Earnings Releases
  Jade Biosciences, Inc. reported financial results for the year ended December 31, 2022.
  - Period: the year ended December 31, 2022
  - Result: reported results
  source text: On March 29, 2023, Aerovate Therapeutics, Inc. announced its financial results for the fourth quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874923000013/0001798749-23-000013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.